Supriya Lifescience IPO opens today: 10 Key points to note before subscribing to the public issue
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The IPO consists of fresh issue of equity shares aggregating up to Rs.200 crore and offer for sale aggregating up to Rs. 500 crore.
Date: Supriya IPO subscription to start from today Dec 16 to Dec 20, 2021
Price band: The price range for the offer has been fixed at Rs 265 – 274 per share.
IPO Lot size: Investors can bid for a minimum of 54 equity shares and in multiples thereof. At the upper end of the price band, one lot is worth Rs 14,796 and maximum of 13 lots, i.e. 702 equity shares and its worth Rs. 1,92,348
Grey market premium: As per the sources, the Supriya IPO is trading at a premium of Rs 250 per shares in the grey market [Also Read: Supriya Lifescience IPO GMP, Grey Market Premium Today]
Fund utilisation: Supriya will use the IPO for funding capital expenditure requirements of the Company and Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the Company
Investor categories: Seventy five percent of the issue size has been reserved for qualified institutional buyers (QIBs), 15 percent for non-institutional investors, and 10 percent for retail investors.
Also Read: Supriya Lifescience IPO Subscription Status
Peers: Solara Active Pharma Sciences, Neuland Laboratories, Aarti Drugs, Wanbury and Divis Laboratories are the peer groups for Supriya Lifescience
Promoters: Satish Waman Wagh is the company promoters
Lead managers: ICICI Securities Limited and Axis Capital Limited are the book running lead managers to the issue.
Registrar: Link Intime India Private Limited is the Registrar for this issue.
Financials: Supriya reported a profit of Rs 1,238.28 million for FY21, up from just Rs 734.03 million in FY20. Revenue during the same period increased to Rs 3,962.21 million from Rs 3,227.13 million.
Follow us on Telegram for all the latest updates
